GSK’s Data Transparency Initiatives:Will they Trigger a Change in Pharma Industry Practices?




Case Details Case Introduction 1 Case Introduction 2 Case Excerpts

ABSTRACT

The case discusses how UK-based pharmaceutical major, GlaxoSmithKline plc (GSK), embraced transparency and openness in October 2012 by announcing its plans to publish its clinical trials data online. With this, the pharma major planned to actively collaborate with scientists and researchers to find new drugs to treat diseases plaguing the developing world. GSK’s move to becoming more transparent with its clinical trials was greeted with a degree of cynicism be a section of industry experts who they felt that the company’s commitment to transparency resulted more from the lawsuits it faced for concealing negative data related to its drugs. In July 2012, GSK paid a fine of US$ 3 billion for illegally marketing its drugs and not disclosing data to the regulators. Notwithstanding criticisms, in October 2012, GSK announced that it would publish the results of all its clinical trials in scientific journals....

Business Strategy Case Studies | Case Study in Management, Operations, Strategies, Business Strategy, Case Studies
or
Business Strategy Case Studies | Case Study in Management, Operations, Strategies, Business Strategy, Case Studies
or
PayPal (13 USD)

Issues

The case is structured to achieve the following teaching objectives:

  • Identify the factors that led to GSK committing itself to being radically open and sharing its clinical trials data publicly.
  • Analyze the effectiveness of GSK’s data transparency initiatives.
  • Apply a framework for implementing data transparency that respects data privacy and prevents data misuse.
Contents
INTRODUCTION
BACKGROUD NOTE
PUTTING PROFITS BEFORE SAFETY?
EMBRACING TRANSPARENCY
THE BENEFITS
OTHERS FOLLOW SUIT
THE RESULTS
CONCLUSION
EXHIBITS

Keywords

GlaxoSmithKline plc, Data transparency, Corporate transparency, Clinical trial data, Clinical Study Register, Data secrecy, Clinical study reports, Data misuse, Patient privacy, AllTrials campaign, Food and Drug Administration

INTRODUCTION - Next Page>>